Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Prevnar Batches To Ship Soon; Contract Fill/Finish Facility Approved

Executive Summary

Wyeth plans to release batches of Prevnar from a Cardinal facility in early May following FDA approval of the third-party vial fill and finish line April 16

You may also be interested in...



Cardinal Manufacturing Operations Are Primary Focus Of Restructuring

The first phase of Cardinal's restructuring plan will have the biggest impact on the company's contract manufacturing operations

Cardinal Manufacturing Operations Are Primary Focus Of Restructuring

The first phase of Cardinal's restructuring plan will have the biggest impact on the company's contract manufacturing operations

Cardinal Fee-For-Service Distribution Transition Slows Earnings Growth

Cardinal's slower-than-expected conversion of its contracts to the fee-for-service distribution model has contributed to a slowdown in earnings growth

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel